Agenus and Gilead pen immuno-oncology alliance
Agenus Inc. granted Gilead Sciences Inc. rights and options to develop and sell up to five of Agenus’ immuno-oncology therapies.
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.